Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Ronzitti is group leader at Genethon. His main interest is the development of adeno-associated virus (AAV)-based gene therapies for rare disorders. In 2013, he arrived at Genethon as a post-doc supervised by Dr. Mingozzi to develop a gene therapy approach for Crigler-Najjar, a metabolic syndrome. This approach is now being translated in the clinic and the first patient will be injected this year.
Cell therapies, Drug toxicology, Cell characterisation and Nanotechnology.